3IJ0 Stock Chart & Stats
€10.40
€0.01(0.12%)
At close: 4:00 PM EDT
€10.40
€0.01(0.12%)
Day’s Range― - ―
52-Week Range€8.25 - €11.55
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€600.33M
Enterprise Value€1.57K
Total Cash (Recent Filing)€55.16M
Total Debt (Recent Filing)€439.44M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Nov 09, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding54,973,545
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.06
Price to Sales (P/S)2.38
P/FCF Ratio-40.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.96Price Target Upside34.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)2.1
Revenue Forecast (FY)€166.62M
Bulls Say, Bears Say
Bulls Say
Governance ImprovementsDHT has improved its governance structure by requiring independent trustees to take at least half their retainer in equity, aligning interests with shareholders.
Management ConfidenceAli Hedayat, with extensive experience from Goldman Sachs and hedge funds, is involved in DHT's strategy and owns shares personally, indicating confidence in the company's direction.
Regulatory ApprovalsCASGEVY has been approved by the FDA and EMA for use in sickle cell disease and transfusion-dependent beta-thalassemia, indicating strong regulatory backing.
Bears Say
Auditing IssuesThere are gaps in DHT's auditing process, with speculation that Deloitte was not effectively sampling invoices for audit.
Fraudulent ChargesDHT has faced fraudulent consulting charges put through by Behzad Khosrowshahi, with capital siphoned into his personal account.
DRI Healthcare News
3IJ0 FAQ
What was DRI Healthcare’s price range in the past 12 months?
DRI Healthcare lowest stock price was €8.25 and its highest was €11.55 in the past 12 months.
What is DRI Healthcare’s market cap?
DRI Healthcare’s market cap is €600.33M.
When is DRI Healthcare’s upcoming earnings report date?
DRI Healthcare’s upcoming earnings report date is Nov 09, 2026 which is in 72 days.
How were DRI Healthcare’s earnings last quarter?
DRI Healthcare released its earnings results on Aug 07, 2026. The company reported €0.485 earnings per share for the quarter, missing the consensus estimate of €0.516 by -€0.032.
Is DRI Healthcare overvalued?
According to Wall Street analysts DRI Healthcare’s price is currently Undervalued.
Does DRI Healthcare pay dividends?
DRI Healthcare does not currently pay dividends.
What is DRI Healthcare’s EPS estimate?
DRI Healthcare’s EPS estimate is 0.66.
How many shares outstanding does DRI Healthcare have?
DRI Healthcare has 54,973,545 shares outstanding.
What happened to DRI Healthcare’s price movement after its last earnings report?
DRI Healthcare reported an EPS of €0.485 in its last earnings report, missing expectations of €0.516. Following the earnings report the stock price went up 0.196%.
Which hedge fund is a major shareholder of DRI Healthcare?
Currently, no hedge funds are holding shares in DE:3IJ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DRI Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.96 (34.25% Upside)
€13.96 (34.25% Upside)
Insider Transactions
Bought Shares
Worth €553.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.05%
12-Months-Change
Fundamentals
Return on Equity
3.36%
Trailing 12-Months
Asset Growth
5.13%
Trailing 12-Months
Company Description
DRI Healthcare
DRI Healthcare Trust is an unincorporated open-ended company. It engages in the provision of differentiated exposure to the fast-growing pharmaceutical and biotechnology industries through ownership and acquisition of royalties on pharmaceutical products with a focus on delivering attractive growth in cash receipts from royalty assets over the long term. The company was founded in 1989 and is headquartered in Toronto, Canada.
3IJ0 Stock 12 Month Forecast
Average Price Target
€13.96
▲(34.25% Upside)









